Vera Therapeutics, Inc.
VERA Nasdaq
SEC CIK 1831828
Follow Vera Therapeutics
Weekly email: filings, results
Revenue, last quarter
$10.3M
Net income
−$93.7M
−16.7% vs same quarter last year
EPS, diluted
−$1.30
−3.2% vs same quarter last year
Operating cash flow
−$99.2M
−60.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$299.6M |
| FY24 | −$152.1M |
| FY23 | −$96M |
| FY22 | −$89.1M |
| FY21 | −$32.6M |
| FY20 | −$53.4M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$241.7M |
| FY24 | −$135.7M |
| FY23 | −$92.2M |
| FY22 | −$67.7M |
| FY21 | −$23.7M |
| FY20 | −$34.9M |
| FY19 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $0 |
| FY24 | $13K |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |